Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Fujifilm close to deal to buy Takeda research reagent unit - Nikkei

Published 02/11/2016, 19:06
Updated 02/11/2016, 19:10
© Reuters. A man stands in front of the headquarters of Fujifilm Holdings Corp in Tokyo
JP225
-
CG
-
4502
-
4901
-
4217
-

(Reuters) - Japan's Fujifilm Holdings Corp (T:4901) is in final talks to buy Takeda Pharmaceutical Co's (T:4502) 70 percent stake in Wako Pure Chemical Industries for about 200 billion yen ($1.94 billion), the Nikkei business daily reported on Wednesday.

A basic agreement is expected to be inked as soon as this month and Fujifilm plans to complete the deal by end of March, the financial daily said.

Hitachi Chemical Co Ltd (T:4217) and U.S. private equity firm Carlyle Group (NASDAQ:CG) also participated in the final round of bidding for the stake in October, the report said.

Fujifilm, Takeda, Hitachi Chemical and Carlyle Group were not immediately available for comment.

Takeda, Japan's largest drugmaker by market value, is looking to sell its holding in Wako Pure Chemicals Industries Ltd to streamline its operations, Reuters reported in July.

Osaka-based Wako Pure makes laboratory chemicals and clinical diagnostic reagents, and reported sales of 75.7 billion yen last year.

© Reuters. A man stands in front of the headquarters of Fujifilm Holdings Corp in Tokyo

($1 = 103.2900 yen)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.